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Abstract 20 
Global trends show that habitual omega-3 intakes are short of recommended guidelines, particularly 21 
amongst vegetarians.  Subsequently, alternative dietary sources of long chain omega-3 22 
polyunsaturated fatty acids (LC3PUFA) from vegetarian sources are needed.  Food technology 23 
methods are advancing and nanoemulsion technologies have improved the bioavailability of certain 24 
lipid-based nutrients.  This study examined whether ingestion of an omega-3 algal oil nanoemulsion 25 
led to improved bioavailability compared to the bulk oil.  Eleven subjects completed a single-blind, 26 
randomised crossover trial, with a 21-day washout between interventions.  Results demonstrated 27 
LC3PUFA absorption from the nanoemulsion was significantly higher than the bulk oil.  Percentage 28 
blood fatty acids were significantly increased for docosahexaenoic acid (DHA) (P ≤ 0.05) while 29 
LC3PUFA: PUFA ratios increased (P ≤ 0.05) and omega-6:omega-3 ratios were reduced (P = 30 
0.028). Larger and longer intervention studies are now needed, but these preliminary findings 31 
demonstrate that nanoemulsion technology may improve the absorption of omega-3 fatty acids. 32 
  33 
Introduction 34 
Latest evidence from Western countries indicates that certain population groups may not be 35 
consuming enough long chain omega-3 (n-3) polyunsaturated fatty acids (LC3PUFA) (Nelson et al. 36 
2007, Elmadfa and Freisling 2009, Bates et al. 2012), with omega-3 intakes in Western regions 37 
being found to be 5-fold lower than Japanese intakes (Meyer, 2011).  Subsequently, failure to 38 
consume enough LC3PUFA for optimal health has led to LC3PUFA deficiency being attributed to 39 
at least thirteen morbidity and mortality outcomes, including CHD, CVD, stroke, depression and 40 
bipolar disorder (Hibbeln et al. 2006).   41 
While the consumption of fish and seafood is one of the easiest ways to improve LC3PUFA intakes, 42 
this is not a feasible option for vegetarians or vegans who have been found to have particularly low 43 
intakes of docosahexaenoic acid (DHA) (Sanders, 2009).  Subsequently, other approaches such as 44 
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the consumption of foods enriched with LC3PUFA may be an alternative way to improve 45 
LC3PUFA intakes and status (Meyer, 2011).   46 
 47 
Nanoemulsions, defined as systems with lipid droplets smaller than 300nm are also gaining interest 48 
and are a novel way to improve the absorption of certain nutrients (Gutiérrez et al. 2008, Anton and 49 
Vandamme 2011).  Nanotechnology methods have already been used and found to improve human 50 
absorption of certain hydrophobic macronutrients, including curcumin (Yu and Huang 2012) and 51 
lutein (Vishwanathan, Wilson et al. 2009).  However, the potential role of nanotechnology methods 52 
to improve the absorption and bioavailability of LC3PUFA using vegetarian delivery vehicles 53 
appears to be understudied.  Previous studies have been confined to animal models and the use of 54 
fish oils which are unsuitable for most vegetarians, or vegans (Dey et al. 2012).   55 
 56 
The Food and Drug Administration (2003) defines bioavailability as “the rate and extent to which 57 
the active ingredient (in this case omega-3) is absorbed and becomes available at the site of action” 58 
(FDA, 2003).  Previous studies have shown that the absorption of free fatty acids from EPA and 59 
DHA depends largely on the presence of intestinal lipases and is generally highest during the 60 
consumption of high-fat meals (Offman et al., 2013).  Work by the same authors has also shown 61 
that higher absorption rates are reflected by increases in blood EPA and DHA levels (demonstrated 62 
using area-under-the curve calculations), with study findings showing that the bioavailability of free 63 
fatty acid forms of EPA and DHA were significantly higher than the bioavailability from ethyl ester 64 
forms, even under low-fat conditions (Offman et al., 2013).   65 
 66 
While the fat-content of the diet has been found to improve the absorption of free fatty acids, 67 
altering the microstructure of foods may also influence this (McClements et al., 2009).  For 68 
example,  lipid emulsions behave differently in the digestive tract according to the droplet size and 69 
the interface layer (Armand et al. 1999, McClemments et al. 2012 ).  Extremely small droplets of 70 
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nutrients can easily be transported in the body through cell membranes giving increased blood 71 
plasma and erythrocyte concentrations (Huang et al. 2010).  It is thought that the incorporation 72 
LC3PUFA into foods using nanoemulsions may improve LC3PUFA bioavailability due to the 73 
reduced particle sizes and high surface to surface volume ratio  (Acosta 2009).   74 
 75 
Given raising concerns over low omega-3 intakes, micro-algal oils, produced in tightly controlled 76 
fermentation facilities may also offer an alternative source of omega-3 fatty acids that are suitable 77 
for vegetarians, vegans and (Geppert et al. 2006, Derbyshire 2009).  Currently, only two studies 78 
appear to have investigated the bioavailability of DHA obtained from algal sources but neither have  79 
used nanoemulsion techniques.  One randomised trial of 109 vegetarians Geppert et al, (2006) 80 
found that DHA-rich almost EPA-free macroalgae oil (0.94 g DHA per day over 8 weeks) improved 81 
some coronary heart disease risk factors (plasma triglyceride levels and triglyceride: high density 82 
lipoprotein ratio) and was regarded as a valuable alternative to fish oil.  In another  28-day 83 
randomized study Arterburn et al, (2007) also concluded that two varieties of algal oil, in doses of 84 
up to 1000 mg DHA per day represented safe and bioequivalent sources of DHA.     85 
 86 
In summary, while there appears to be some emerging evidence supporting the use of algal DHA as 87 
a suitable and bioavailable source of DHA, the potential effects nanoemulsion techniques using 88 
vegetarian food vehicles do not appear to have been studied using human populations.  To this end, 89 
the current study aims to establish whether the bioavailability of an omega-3 rich algal oil is 90 
improved by nanoemulsion technology using yogurt as a food vehicle.   91 
Results will be compared against a control bulk oil product created using identical quantities of the 92 
same vegetarian LC3PUFA algal oil, but without the application of nanotechnology.  93 
 94 
Materials and methods 95 
Yogurt nanoemulsion preparation 96 
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Currently, there is a trend for the enrichment of yogurt products, which is in response to consumer 97 
expectations for functional or wellness foods (Chandan et al. 2008).  In the present study, a 98 
strawberry yogurt was created using combined levels of natural flavouring (0.4g/100g yogurt) and a 99 
sweetening product (13g/100g yogurt).  Unbleached natural phospholipid liquid soy lecithin was 100 
obtained from Now Foods of Bloomingdale, USA and consisted of 15 per cent phosphatidyl 101 
choline, 13 per cent phosphatidyl ethanolamine, 9 per cent phosphatidyl inositol and 19 per cent 102 
other phospholipids and lipids.  Soy lecithin was used in combination with ultrasound to create a 103 
nanoemulsion (patented method (Lane et al. 2012)) containing 50 per cent DHA
TM
 -S algae oil and 104 
water (see Table 1 for the fatty acid composition of DHA
TM
-S oil).  DHA
TM
-S oil is a triglyceride 105 
oil produced by the algal species schizochytrium sp.  This oil contains around 35 per cent DHA and 106 
was obtained from Martek Biosciences through DSM Great Britain Limited.   107 
Nanoemulsion droplet sizes were determined using a Malvern Mastersizer 2000 courtesy of 108 
Glyndŵr University, Wrexham, UK.  Nanoemulsion droplet size distributions were measured in 109 
accordance with the methods used by Akhtar et al, (2006) and Akhtar and Dickinson, (2003) using 110 
a Malvern Mastersizer MS2000 laser light-scattering analyser with a small sample dispersion unit 111 
set to 2000rpm.  A drop of each sample amounting to approximately 10µl was pipetted into the 112 
dispersion unit.  For the emulsion samples an absorption parameter value of 0.001 and the refractive 113 
index ratio of 1.472 for flaxseed oil and 1.488 for the algae oil was used (Breivik 2007).  Samples 114 
were measured in duplicate to ensure accuracy with a 15-second pause between measurements.  115 
Droplet size is reported as the d32 volume/surface diameter mean or Sauter mean.  Droplet size 116 
distributions can be found in Figure 1  117 
A total of 4.29g nanoemulsion (mean droplet size 258nm) was added per 100g of yogurt and a bulk 118 
oil enriched product was created by adding 2.15g bulk oil per 100g yogurt.  Participants ingested 119 
200g of yogurt during each treatment phase.   120 
 121 
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Dosage  122 
A dosage of 1264.69 ± 44.91mg DHA was used for each treatment.  This was based on the key 123 
findings from a preliminary bioavailability trial (unpublished results) and previously published 124 
LC3PUFA randomised crossover trials (RCT).  For example, Raatz et al, (2009) used a crossover 125 
trial to ascertain whether pre-emulsification improved the bioavailability of LC3PUFA and a dose 126 
of 712mg DHA and 440mg EPA was given.  A further trial by Schuchardt et al, (2011) compared 127 
the bioavailability of fish oil and krill oil using a crossover trial with a formulated dose of 1680mg 128 
EPA and DHA.  In terms of tolerable upper intakes the European Food Safety Authority (EFSA) 129 
state that of 1g/day DHA should be suitable for the general population and that while doses of 2 to 130 
4g per day have been associated with increases in LDL-cholesterol concentrations by 3 per cent, 131 
this should not have an adverse effect on CVD risk (European Food Safety Authority 2006).  132 
Although Calzada et al, (2010) found that high levels of up to 3 or 4g/d DHA could have pro-133 
inflammatory consequences.    134 
 135 
136 
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Subjects 137 
Trial subjects were recruited from Manchester Metropolitan University (MMU) Hollings Faculty.  138 
Invited participants were healthy adult men and women (aged 18 to 60 years) who did not consume 139 
fish oil or vegetarian LC3PUFA dietary supplements, regularly eat oily fish or be willing to 140 
complete a one month washout period prior to the trial (see Table 2 for study inclusion criteria).  141 
Potential volunteers were interviewed and date of birth, sex, height, weight, medical history, 142 
pregnancy status, smoking history, dietary supplement use, alcohol consumption, exercise activity 143 
levels, and concomitant medications obtained.  Participants with relevant food allergies, obesity 144 
(BMI >30) any significant health problems or underlying conditions that may affect fat absorption 145 
(determined using the British National Formulary (2012)) were excluded from the trial. All data 146 
was fully anonymized. 147 
 148 
The LC3PUFA consumption status of the subjects was assessed using a validated food frequency 149 
questionnaire from Ritter-Gooder et al, (2008), which gathered daily dietary intakes of LC3PUFA, 150 
ALA, EPA and DHA.  Participants whose dietary intake of EPA and DHA exceeded 200 mg DHA 151 
per day were excluded or asked to complete a one-month washout period before taking part in the 152 
trial, using similar approaches to Schuchardt et al, (2011).   153 
 154 
Study design   155 
This intervention study was conducted according to the guidelines laid down in the Declaration of 156 
Helsinki (World Medical Association 2008) and all procedures involving human subjects were 157 
approved by the Manchester Metropolitan University Ethics Committee on 30th July 2012. Written 158 
informed consent was obtained from all subjects.  The trial was designed in accordance with the 159 
CONSORT statement for randomized controlled trials (Schulz, Altman et al. 2011). 160 
 161 
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A randomised single blinded crossover trial was utilised to determine the bioequivalence of DHA 162 
from bulk and nanoemulsified oil enriched yogurt.  Subjects were randomised and allocated to 163 
treatments in an A/B or B/A pattern using the ‘Sealed Envelope’ randomisation program (Sealed 164 
envelope 2012).  A total of six blood samples were taken for each treatment phase with the aim of 165 
capturing optimum levels to make use of the area under the curve calculation.  As described by 166 
Wakil et al, (2010), participants completed a 21-day minimum washout period between each 167 
treatment phase before the trial was repeated using the other treatment (see Figure 2).   168 
 169 
The minimum washout period of 21 days between treatments was based on previously published 170 
LC3PUFA crossover studies and it was anticipated that this would be sufficient to allow baseline 171 
values to return to normal levels (Garaiova et al. 2007, Schuchardt et al. 2011).  Applicants were 172 
also asked to avoid the restricted foods during the washout period in accordance with a recent trial 173 
by Davidson et al, (2012).  This was assessed using three-day dietary recalls, which were analysed 174 
using Netwisp (Version 3) to include a full fatty acid analysis.   175 
 176 
Blood testing methods  177 
Blood samples were taken for each tranche of the trial at baseline 2, 4, 6, 24 and 48-hour intervals.  178 
Samples were obtained after overnight fasting for baseline, 24 and 48-hour measurements.   ACCU-179 
CHEK Safe-T-Pro Plus lancets with three depth settings of 1.3, 1.8, and 2.3mm were used to obtain 180 
finger prick blood samples by puncturing the fingertip.  Depth settings of 1.8mm were used for 181 
females and 2.3mm for males.  Blood samples were collected using ‘The Omega Blood Count’ test 182 
provided by Glasgow Health Solutions (2012).  The finger prick test provided blood measures for 183 
total LC3PUFA:PUFA and omega-6 arachidonic acid (ARA):EPA ratios with ALA, EPA and DHA 184 
percentages.  After collection, fingertip samples were placed in the test kit box with a desiccation 185 
pouch and allowed to dry for a minimum of three hours.   186 
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Once dry, the collection cards were placed in a sealed plastic storage bag with a desiccant pouch 187 
and sent directly by post to Stirling University.   188 
 189 
Blood analysis was carried out at The Institute of Aquaculture, Nutrition Analytical Service, 190 
Stirling University, using purpose built analytical equipment.  Samples were tested in accordance 191 
with the methods stated by Bell et al, (2011).  The dried whole blood sample was detached from the 192 
collection devise using scissors and forceps and placed in a screw top vial containing 1ml of 193 
methylating solution (1.25 M in methanol-HCI).  The temperature of the vials was then increased to 194 
70°C using a hot block, where the sample remained for one hour.  The vials were then allowed to 195 
cool to room temperature, then 2ml of distilled water and 2ml saturated potassium chloride solution 196 
were added.  Fatty acid methyl esters (FAME) were extracted using 2x2ml isohexane.   197 
 198 
To extract the remaining haem and cholesterol, 500mg/6ml of solid phase extraction silica gel was 199 
used after which the samples were dried down in preparation for analysis using gas-liquid 200 
chromatography (GLC).  FAME were separated then quantified by GLC.  (ThermoFisher Trace, 201 
Hemel Hampstead, Herts, UK) using a 60m x 0.32mm x 0.25µm film thickness capillary column 202 
(ZB Wax; Phenomenex, Macclesfield, Cheshire, UK).  Hydrogen was used as the carrier gas at a 203 
flow rate of 4.0ml/min and the temperature programme was from 50 to 150˚C at 40˚C/min then to 204 
195˚C at 2˚C/min and finally to 215˚C at 0.5˚C/min.   205 
Individual FAME were identified by comparison to well-characterised in-house standards as well as 206 
commercial FAME mixtures.  207 
  208 
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Statistical analysis 209 
Data are presented as mean ± standard error for continuous variables, number of subjects (n) and 210 
percentage (%) for categorical variables.  All whole blood levels were corrected to baseline levels.  211 
The area under the curve (AUC) was calculated for DHA and LC3PUFA:PUFA.   212 
Values were determined for each person during the intervention period according to the trapezoid 213 
rule (Matthews et al. 1990, Brouns et al. 2005).  ARA:EPA ratios were analysed using baseline 214 
adjusted values due to decreases in these levels.  Compatibility checks using Kolmogorov-Smirnov 215 
and Shapiro-Wilk tests established that the baseline adjusted means and AUC results had normal 216 
and non-normal distributions.  Statistical analysis was completed using mixed repeated measures 217 
two-way analysis of variance (MMANOVA) as described by Pallant (2010).   218 
To further identify specific differences paired t-tests and Wilcoxon Signed Rank tests were 219 
completed to evaluate differences between treatments and time intervals in comparison to baseline.  220 
Values of P ≤ 0.05 were considered to be statistically significant.  All statistical analyses were 221 
carried out using SPSS software (version 19.0).   222 
 223 
Results  224 
A total of thirteen volunteers were recruited, with two potential subjects being excluded.  One was 225 
taking regular medication known to affect the metabolism of fatty acids; the other was unable to 226 
travel to the faculty before having breakfast.  Previous literature demonstrates that a number of 227 
studies have utilised a crossover design to assess absorption of LC3PUFA using a similar number of 228 
participants to this study (Garaiova et al. 2007, Raatz, et al. 2009, Wakil et al. 2010, Schuchard et 229 
al. 2011).  Comparative randomised crossover studies by Raatz et al, (2009) examined the 230 
absorption of LC3PUFA from emulsified fish oil compared to bulk oil supplements using 10 231 
participants and Garaiova et al, (2007) compared absorption of pre-emulsified fish oil to bulk oil 232 
with 13 volunteers.   233 
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The average age of the 11 participating subjects was 33 years 6 months (±10.3 years), BMI was 234 
23.89 (±2.11), six volunteers were male and five female.  There was no evidence of significant 235 
differences between baseline blood values or correlations between oily fish or supplement intake, 236 
which confirms that the washout periods were effective and that there was no evidence of 237 
LC3PUFA carryover between treatments.  The paired t-test showed there were no significant 238 
differences between dietary intakes at baseline for both treatments for energy (Kcal) (P = 0.655), 239 
total fat (P = 0.908), monounsaturated fatty acids (MUFA) (P = 0.697), polyunsaturated fatty acids 240 
(PUFA) (P = 0.403), saturated fats (P = 0.863), protein (P = 0.346) and carbohydrates. (P = 0.817).  241 
This indicated that the self-reported dietary intakes were consistent among participants for each 242 
treatment.  243 
 244 
DHA bioavailability 245 
The mean baseline adjusted percentage DHA increases for the bulk and nanoemulsion treatments 246 
can be found in Figure 3.  The nanoemulsion enriched yogurt gave rapid increases in DHA levels, 247 
which peaked 2 hours after ingestion.  Paired t-tests and Wilcoxon Signed Rank tests were 248 
completed to assess the time intervals (see Table 4), which demonstrated significant differences 249 
between nano and bulk treatments for the 0 to 2 and 2 to 4 hour values (P = 0.001 and P = 0.040 250 
respectively).  DHA from the nanoemulsion enriched yogurt was statistically significantly more 251 
bioavailable than the bulk oil for up to four hours after ingestion.  A comparison of the treatments at 252 
all times using mixed models ANOVA demonstrated that the percentage increase of DHA in blood 253 
fatty acids was not statistically significant for the two treatments (P = 0.803) and that there was also 254 
no significant effect for gender (P = 0.311).  Overall time intervals following digestion were found 255 
to be a statistically significant factor (P = 0.010).  The intercept of treatment, time intervals and 256 
gender was also a significant factor (P = 0.006).   257 
 258 
LC3PUFA bioavailability 259 
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Figure 4 demonstrates the baseline adjusted LC3PUFA percentage increases for both treatments.  260 
LC3PUFA levels peaked at 4 hours for both treatments, indicating a slower rate of absorption to 261 
DHA.   Analysis of the time intervals using the paired t-test and Wilcoxon Signed Rank tests 262 
demonstrated that LC3PUFA was significantly more bioavailable for the nanoemulsion from 2 to 4 263 
and 4 to 6 hours following ingestion (P = 0.020 and P = 0.030 respectively).  A comparison of the 264 
treatments at all times using mixed models ANOVA demonstrated that the percentage increase of 265 
LC3PUFA in blood fatty acids was approaching significance for treatment (P = 0.067).   266 
There was also a significant effect for gender, with males having significantly higher AUC for the 267 
combined treatments than women (P = 0.014) and time intervals (P = 0.010).  The intercept of 268 
treatment, time intervals and gender was a significant factor (P = 0.001).   269 
 270 
Changes in ARA:EPA ratios 271 
The ratio of omega-6 (n-6) to n-3 is important for long-term health and the arachidonic 272 
acid/eicosapentaenoic acid (ARA/EPA) ratio may be used as an indicator of fatty acid balance and 273 
long-term health (Simopoulos 2011).  Baseline adjusted blood ARA:EPA percentage values are 274 
shown in Figure 5.  Statistical analysis was completed using the baseline adjusted ARA:EPA 275 
values.  A comparison of the treatments at all times using mixed models ANOVA demonstrated that 276 
the percentage decrease in ARA:EPA blood fatty acids ratios was significantly higher for the 277 
nanoemulsion treatment (P =0.028) and that time and gender were approaching significance (P = 278 
0.063 and P = 0.058 respectively).  The intercept of treatment, time and gender was a significant 279 
factor (P = 0.001). Women had larger but non-significant reductions in ARA:EPA ratios for both 280 
treatments than men (nano treatment males -2.58, females-6.84 per cent, bulk treatment males -281 
0.98, females -2.07 per cent) although these were only approaching significance (P = 0.063).  282 
  283 
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Discussion 284 
To the knowledge of the authors, this study was the first to demonstrate that an algal based 285 
vegetarian LC3PUFA oil nanoemulsion was absorbed more effectively than the same bulk oil 286 
control.  Nanoemulsion enriched foods may offer an effective vehicle to increase habitual 287 
LC3PUFA intakes which currently fall below recommended guidelines for the general population 288 
(Bates et al. 2012).   289 
 290 
This study demonstrated that, compared with a bulk oil enriched yogurt, the consumption of a 291 
yogurt enriched with a nanoemulsion of algae oil (mean droplet size 258nm) offers an enhanced 292 
rate and extent of absorption for LC3PUFA.  The increased levels of DHA and LC3PUFA coupled 293 
with decreased ARA:EPA markers may be beneficial to health (Simopoulos 2011).  Blood marker 294 
levels peaked between two and four hours after ingestion for both treatments (Table 4).  The levels 295 
of DHA percentage fatty acids for the nanoemulsion were 1.81 and 1.61 times the bulk oil levels, 296 
two and four hours following ingestion (P = 0.001 and P = 0.04 respectively).   297 
 298 
Blood LC3PUFA levels were significantly elevated to 1.78 and 1.62 times the bulk oil respectively, 299 
four and six hours after ingestion (P = 0.020 and P = 0.030).  The mean ratio of ARA/EPA in blood 300 
fatty acids was also significantly lowered by the nanoemulsion in comparison to the bulk oil 301 
product for the duration of the trial (P = 0.011).   302 
  303 
The findings from this RCT are in line with those reported by Garaiova et al, (2007),  who found 304 
that blood DHA levels peaked three hours after ingestion, although in this instance a larger dosage 305 
of pre-emulsified fish oil was used.  When compared to bulk oil capsules, EPA and DHA blood 306 
plasma triacylglycerol levels were found to be significantly higher in the pre-emulsion group (P 307 
<0.001 and P = 0.0355 respectively).  For the pre-emulsification study, LC3PUFA from the pre-308 
emulsion treatment which had a median droplet size of 1.3µm was significantly more bioavailable 309 
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than bulk oil using AUC calculations (P = 0.018).  Participants were given 30ml of the fish oil 310 
based formula with fatty acids comprising of 16.8 per cent EPA and 11 per cent DHA in bulk or 311 
pre-emulsified form with a crossover between treatments.   312 
 313 
Raatz et al, (2009) made further findings, which validate the results of this trial in a bulk 314 
oil/emulsion crossover study.  Statistically significant increases were found in the bioavailability of 315 
LC3PUFA from a 4g dose of bulk or emulsified fish oil (droplet size not stated).  As with the 316 
current trial ARA/EPA ratios were significantly more reduced with the emulsion treatment (P = 317 
0.01) and enhanced absorption was noted for EPA (P < 0.01) and total LC3PUFA (P = 0.05). 318 
 319 
In terms of the possible mechanisms, the observed rises in the bioavailability of nanoemulsions may 320 
have occurred due to increased lipase activity at the surface area and interfacial layer of oil droplets 321 
as droplet surface areas increase as droplet sizes decrease (Garaiova et al. 2007, Raatz et al. 2009, 322 
Yu and Huang 2012).  Very fine droplets also have high specific surface areas and high curvatures 323 
giving different surface reactivity than bulk oils, which can lead to amended bile salt accumulation 324 
and activity (McClements and Xiao 2012).  In addition, small droplets of nutrients can easily be 325 
transported in the body through cell membranes, giving increased blood plasma and erythrocyte 326 
concentrations (Huang et al. 2010).  Once in circulation, blood lipids are in constant exchange with 327 
major tissues containing LC3PUFA, namely the intestine, liver and peripheral organs.  This may 328 
explain decreases in blood levels that were particularly noticeable in some participants 24 hours 329 
after ingestion.   330 
 331 
This study used a validated fingertip blood sampling method, which has previously been 332 
demonstrated to give good correlations to erythrocyte plasma and whole blood fatty acid levels 333 
(Bell et al. 2011).  Due to the nature of fingertip blood sampling, it was possible to obtain 334 
percentage fatty acid levels for the blood markers but not precise levels.    335 
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It was not therefore possible to calculate exactly how much of the 1264 mg dose of DHA entered 336 
the bloodstream.  However, for this initial trial, fingertip blood sampling was a far less invasive 337 
sampling method in comparison to cannulation blood test methods, which may have been 338 
unsuitable for several of the participants in this trial.   339 
 340 
With regard to study limitations, in the present study, participants underwent a four-week washout 341 
period, which may have left some internal organs and tissues LC3PUFA depleted and further 342 
increased tissue uptakes from blood.  The dosages used in this trial were based on previous research 343 
and ethical considerations.   344 
The use of lecithin as the emulsifier in the nanoemulsion samples and not the bulk oil control may 345 
act as a potential confounder in this trial.  Lecithin may have improved or decreased the 346 
bioavailability of the fatty acids contained in the algae oil.  A study by Mun et al, (2007) found that 347 
lecithin decreased the access of pancreatic lipase to emulsified fats in comparison to protein based 348 
emulsifiers such as caseinate and whey protein isolates.   349 
It was necessary to use lecithin to create stable nanoemulsion systems.  The bulk oil product was 350 
stable to separation when formulated, so additional emulsifying agents were not considered 351 
necessary.  The aim of the trial was to compare nanoemulsions to bulk oil.  It was decided not to 352 
give a sole dose of bulk oil only to participants as it may have caused unpleasant taste and 353 
mouthfeel sensations.  Yogurt was chosen as the food vehicle for this trial as it facilitated the 354 
provision of a relatively high dose of nanoemulsion and potentially offered improved oxidation 355 
stability (Sabeena Farvin et al. 2010).  The use of yogurt as an enrichment vehicle may have 356 
affected fatty acid absorption.  Schram et al, (2007) found that yogurt provided the best matrix for 357 
fast of absorption of lipids in general including n-3 when comparing supplements, fitness bars 358 
yogurt and bread and butter.   359 
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Therefore to ensure consistency, the bulk oil was incorporated into the same yogurt product, which 360 
also ensured that volunteers remained blinded to the treatment pattern.  Lecithin was not added to 361 
the bulk oil product to ensure that the oil remained as much in bulk form as possible and did not 362 
instantaneously form fine emulsion droplets as this might act as a further confounder.    363 
Larger doses (>4g LC3PUFA) used by Davidson et al, (2012) and Galli et al, (2012) may have 364 
achieved more detectable changes in blood concentrations after a single one off treatment.  365 
However, a dose of 1264 mg DHA did demonstrate significant differences in blood percentage 366 
levels soon after ingestion when the nanoemulsion was compared to the bulk product.  In future, 367 
long term intervention trials are needed to investigate the sustained effects of consumption of 368 
vegetarian LC3PUFA nanoemulsion fortified foods on LC3PUFA bioavailability using a RCT 369 
study design. 370 
 371 
To conclude, the present study demonstrated that when compared to a bulk oil enriched yogurt, the 372 
consumption of a yogurt with an added nanoemulsion of algae oil offers an enhanced rate and 373 
extent of absorption of DHA and total LC3PUFA, with a decline in ARA:EPA levels, which may 374 
broaden health benefits.  It is believed that this study is the first to investigate the bioavailability of 375 
an algal based vegetarian LC3PUFA nanoemulsion, using fingertip blood sampling and yogurt as a 376 
food vehicle.  While larger and extended studies are needed, these findings indicate that 377 
nanoemulsion enriched foods may improve LC3PUFA intake and uptake, helping to bridge the gaps 378 
with dietary recommendations that currently exist.    379 
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